Cullinan Therapeutics (CGEM) Institutional Ownership

86.31% of Cullinan Therapeutics' stock is owned by institutional investors. Learn more on CGEM's institutional investor holdings.

Of the 138 institutional investors that purchased Cullinan Therapeutics' stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Lynx1 Capital Management LP ($2.59M), Deerfield Management Company L.P. Series C ($2.24M), Affinity Asset Advisors LLC ($1.67M), Marshall Wace LLP ($1.31M), Boothbay Fund Management LLC ($1.24M), Braidwell LP ($1M), and State Street Corp ($916.06K).

Institutional investors have bought a total of 9,859,157 shares in the last 24 months. This purchase volume represents approximately $90.62M in transactions.

Of the 47 institutional investors that sold Cullinan Therapeutics' stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: Orbimed Advisors LLC ($1.68M), Affinity Asset Advisors LLC ($1.15M), Deerfield Management Company L.P. ($928.54K), Franklin Resources Inc. ($812.12K), Citadel Advisors LLC ($465.39K), Dimensional Fund Advisors LP ($427.77K), and Renaissance Technologies LLC ($307.60K).

Institutional investors have sold a total of 7,500,321 shares in the last 24 months. This volume of shares sold represents approximately $69.41M in transactions.